AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03491189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helical blade fixation
Description: surgical fixation
Study NCT05167110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
Study NCT01526226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory support HFNC
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
Study NCT01526226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support HFNC
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
Study NCT01526226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory support NCPAP
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
Study NCT01526226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support NCPAP
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
Study NCT05167110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
Study NCT00539097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven (Ross Products) protein supplement
Description: Juven supplement oral x 3 weeks postop
Study NCT00918723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00918723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00918723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00918723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT00679562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
Study NCT00679562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Application of patches containing distilled water for 24 hours
Study NCT02950623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
Study NCT02950623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
Study NCT02950623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rapid heat denture
Description: patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
Study NCT02950623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid heat denture
Description: patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
Study NCT02795910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach education training
Description: Printed copies of the patient management tool (PMT) and outreach education training
Study NCT02795910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No outreach education training
Description: Printed copies of the patient management tool (PMT) without outreach education training
Study NCT04273243 — intervention group
Intervention type: GENETIC
Intervention: AT-GTX-501
Description: No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study NCT04215549 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: cross sectional study，no intervention
Study NCT02420652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study NCT02420652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02420652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02420652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study NCT02420652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given metformin hydrochloride placebo PO
Study NCT02420652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given aspirin placebo PO
Study NCT01284556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: tablet
Study NCT01284556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: tablet
Study NCT04512885 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey via questionnaire
Study NCT02660580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11022
Description: Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
Study NCT03195842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recordable card
Study NCT01933815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
Study NCT01933815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
Study NCT01933815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
Study NCT00655798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt containing Bifidobacterium animalis ssp.
Description: Yogurt containing the probiotic Bifidobacterium animalis ssp.
Study NCT03383133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SULT Allosteric Inhibition
Description: A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
Study NCT02618187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-287
Study NCT02618187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02618187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pre-Treat
Study NCT01822353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: Milk, egg or nut oral immunotherapy
Study NCT02618187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pre-Treat
Study NCT02223585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-based protein diet
Study NCT02223585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan-based protein diet
Study NCT05025137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexi-Bar Exercise
Description: In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot).
Study NCT05025137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Component exercise
Description: Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
Study NCT01602575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based Stress Reduction Training (MBSR)
Description: 8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
Study NCT03162159 — intervention group
Intervention type: OTHER
Intervention: Collection of growth and bone maturation data
Study NCT01310998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: 4x4 intervals
Study NCT02833662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure of ODI and heart rhythm
Description: Record nocturnal respiratory and cardiac parameters before and after surgery.
Study NCT04685733 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive hemodynamic measurements
Description: Non-invasive hemodynamic measurements
Study NCT02618187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Pre-Treat
Study NCT02539407 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetics
Study NCT00160615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: Film-coating tablets~* Concentration: 250 mg/ 500 mg~* Route of administration: oral use
Study NCT01936974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patient to receive gemzar
Study NCT01936974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patient to receive gemzar
Study NCT01728181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
Study NCT01728181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tivozanib
Description: The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
Study NCT01728181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg/day for 28 day cycle. No rest period.
Study NCT01728181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150 mg/day for 28 day cycle. No rest period.
Study NCT01728181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: 150 mg/day for 28 day cycle. No rest period.
Study NCT01728181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care treatment
Description: This treatment will be determined by the study doctor and is considered standard of care.
Study NCT02191059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Study NCT02191059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT01923545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-G-CSF
Description: Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
Study NCT01923545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
Study NCT03168763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Study NCT03168763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, after each video viewing, and at completion.
Study NCT02781883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 in combination with Ventoclax plus decitabine
Description: BP1001 in combination with Ventoclax plus decitabine
Study NCT01936974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Patient to receive avastin
Study NCT02781883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 plus decitabine
Description: BP1001 plus decitabine in ventoclax intolerant or resistant subjects
Study NCT00754455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine (recombinant)
Description: Single injection Day 0; 0.5mL
Study NCT00754455 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a single injection of 0.5 mL.
Study NCT02417948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Educational Brochure
Description: Receive brochure with skin cancer education and preventative information
Study NCT02417948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Educational Brochure
Description: Receive brochure with skin cancer education and preventative information
Study NCT02417948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational video
Description: Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
Study NCT05371171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin graft
Description: In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
Study NCT05371171 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no skin graft
Description: In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
Study NCT04975529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education
Description: Two-group quasi experimental intervention with schools assigned to intervention or comparison.
Study NCT02599805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrox™ Oxygen Delivery System (ODS)
Description: Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
Study NCT02481427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicondylar Knee Replacement
Description: UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
Study NCT02481427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
Study NCT00188708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypoxia measurement
Description: transrectal oxygen measurement
Study NCT01771185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal jejunal bypass plus sleeve gastrectomy
Description: Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
Study NCT01771185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment (Metformin ; gliclazide)
Description: Metformin 2 g/day; gliclazide 30 mg
Study NCT03096015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Comprehensive Aphasia Program
Study NCT01445886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo Naturalis Extract in Oil
Description: The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
Study NCT01445886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Solution
Description: The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
Study NCT01827358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium
Description: Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
Study NCT01827358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium
Description: Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
Study NCT03403257 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No intervention
Study NCT01936974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patient to receive avastin
Study NCT01936974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patient to receive carboplatin
Study NCT01936974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patient to receive cisplatin
Study NCT01936974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Patient to receive Oxaliplatin
Study NCT01466231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.